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Globally, South Africa (SA) has the highest burden 
of childhood HIV infection and the greatest number 
of pregnant women living with HIV, with approxi­
mately 280 000 annually[1] needing antiretrovirals 
to prevent mother­to­child transmission (MTCT) of 
HIV. Although similar to those in other sub­Saharan African (SSA) 
countries, SA adolescent pregnancy rates are high compared with 
other world regions, with approximately 30% of all 15 ­ 19­year­
old women reporting having ever been pregnant.[2,3] Women are 
at a much greater risk of acquiring HIV than men, particularly 
at younger ages, as young women have a range of contextual and 
behavioural factors increasing their risk of HIV acquisition.[4] A high 
proportion of the lifetime risk of acquiring HIV in women occurs 
while they are young.[4] Women aged 15 ­ 19 years have the highest 
incidence of HIV in SA, estimated to remain at over 2% per annum 
until at least 2025,[5] up to four times that of boys in the same age 
range. (Beyond age 50 years, HIV prevalence in women is similar to 
or lower than that of men.[5,6])
Maternal and perinatal outcomes in SA are poor,[7] and HIV­infected 
women have poorer pregnancy outcomes than HIV­uninfected 
women.[8] The United Nations has declared the health of adolescent girls 
and pregnant women to be a global public health priority.[9] There are, 
however, few cohort data investigating MTCT and pregnancy outcomes 
among young HIV­infected women and adolescents in SSA, and minimal 
SA cohort data from prevention of MTCT (PMTCT) programmes 
outside of KwaZulu­Natal Province, Cape Town and Johannesburg.
The aim of this study was to investigate the association between 
younger maternal age and MTCT and maternal and infant health 
outcomes in routine healthcare settings in the Nelson Mandela Bay 
Metropolitan (NMBM) district of the Eastern Cape Province.
Methods
Study design, setting and inclusion criteria
A cohort of pregnant women and their infants were followed up at 
three facilities offering maternal and child health services in sub­
district B of the NMBM (Laetitia Bam Community Health Centre, 
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status when booking (adjusted risk ratio (aRR) 1.37; 95% confidence interval (CI) 1.21 ­ 1.54), a reduced rate of antenatal antiretroviral 
therapy (ART) uptake (adjusted hazard ratio 0.46; 95% CI 0.31 ­ 0.67), reduced early infant HIV diagnosis (aRR 0.94; 95% CI 0.94 ­ 0.94), 
and increased MTCT (aRR 3.07; 95% CI 1.18 ­ 7.96; adjusted for ART use). Of all vertical transmissions, 56% occurred among young 
women. Additionally, adolescents had increased risks of first presentation during labour (aRR 3.78; 95% CI 1.06 ­ 13.4); maternal mortality 
(aRR 35.1; 95% CI 2.89 ­ 426) and stillbirth (aRR 3.33; 95% CI 1.53 ­ 7.25).
Conclusion. An increasing proportion of pregnant HIV­positive women in NMBM were young, and they had increased MTCT and poorer 
maternal and infant outcomes than older women. Interventions targeting young women are increasingly needed to reduce pregnancy, HIV 
infection and MTCT and improve maternal and infant outcomes if SA is to attain its Millennium Development Goals.
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Rosedale Community Health Centre and Uitenhage Provincial 
Hospital). These were sentinel surveillance facilities for evaluating 
the effectiveness of the PMTCT programme.[10] The facilities were 
supported by Kheth’Impilo, a non­profit organisation that supports 
the SA Department of Health. Kheth’Impilo has supported direct 
HIV service delivery by providing clinical staff and community­
based adherence support,[10] and now includes supporting general 
health system strengthening and technical assistance emphasising 
quality improvement, human resource development, supply chain 
management and monitoring and evaluation.
Table 1. Maternal and infant characteristics among HIV-positive pregnant women* according to age category
Young women Older women
(age >24 years)Age ≤19 years (adolescents) Age 20 - 24 years p-trend
n (%) 65 (6.8) 247 (25.8) 644 (67.4)
Year of first antenatal visit, n (%) 0.073
2009 & 2010 22 (6.4) 75 (21.9) 246 (71.7)
2011 & 2012 43 (7.0) 172 (28.1) 398 (64.9)
Unaware of positive HIV status at first antenatal visit,  
n (%) 49 (75.4) 142 (57.5) 288 (44.7) <0.0001
Gestational age at booking (weeks), median (IQR) 
(N=736)
22 (18 ­ 26) 21 (16 ­ 26) 22 (17 ­ 27) 0.76
CD4+ cell count at booking, median (IQR) (N=922) 383 (296 ­ 465) 377.5 (246 ­ 519) 339 (217 ­ 477) 0.005
CD4+ cell count <200 cells/µL, n (%) 6 (9.5) 37 (15.5) 134 (21.5) 0.010
CD4+ cell count >350 cells/µL, n (%) 36 (57.1) 128 (54.2) 297 (47.7) 0.115
Received support from community­based adherence 
support worker, n (%) (N=956)
14 (21.5) 53 (21.5) 129 (20.0) 0.87
Antiretroviral regimen, n (%) <0.0001
On lifelong ART at first booking visit 0 (0) 17 (6.9) 136 (21.1)
Commenced lifelong ART during pregnancy 18 (27.7) 62 (25.1) 155 (24.1)
Antenatal ZDV and sdNVP 34 (52.3) 114 (46.2) 222 (34.5)
Antenatal ZDV only 6 (9.2) 16 (6.5) 47(7.3
sdNVP only 4 (6.2) 8 (3.2) 15 (2.3)
Nil 1 (1.5) 3 (1.2) 7 (1.1)
Unknown 2 (3.1) 27 (10.9) 62 (9.6)
Time till starting ZDV after first antenatal visit as 
prophylaxis for MTCT (days), median (IQR) (N=430)†
0 (0 ­ 46.5) 1.5 (0 ­ 44) 7 (0 ­ 50) 0.26
Time till starting lifelong ART after first antenatal visit 
(days), median (IQR) (N=148)†‡
64 (28 ­ 92)  48 (26 ­ 77) 34 (17 ­ 60) 0.001
Time receiving lifelong ART prior to delivery (weeks), 
median (IQR) (N=260)§
15.1 (10.7 ­ 21.1) 14.4 (5.7 ­ 19.7) 21.1 (10.8 ­ 
125)
<0.0001
Time receiving lifelong ART prior to delivery (among 
women who started lifelong ART during pregnancy) 
(weeks), median (IQR) (N=155)
15.1 (10.7 ­ 21.1) 9.3 (5.1 ­ 16.1) 12.0 (5.3 ­ 17.3) 0.89
Received ART for <14 weeks prior to delivery, n (%)§ 5 (50.0) 28 (48.3) 57 (29.7) 0.0038
Presented for the first time during labour, n (%) (N=956) 3 (4.6) 6 (2.4) 11 (1.7) 0.129
Elected to breastfeed, n (%) (N=909)¶ 44 (74.6) 146 (62.4) 313 (50.8) <0.0001
Recorded maternal deaths, n (%) (N=581) 1 (2.5) 1 (0.6) 0 (0) 0.0132
Stillborn infant, n (%) (N=946) 6 (9.4) 8 (3.3) 32 (5.0) 0.63
Liveborn infants with recorded first HIV DNA PCR test 
result, n (%) (N=910)||
 24 (40.7) 108 (45.2) 336 (54.9) 0.0025
Positive HIV DNA PCR test, n/N (%) (95% CI) (N=468) 2/24 (8.3) 
(1.0 ­ 7.0)
7/108 (6.5) 
(2.6 ­ 12.9)
7/336 (2.1) 
(0.8 ­ 4.2)
0.011
IQR = interquartile range; ART = antiretroviral therapy; ZDV = zidovudine; sdNVP = single­dose nevirapine; MTCT = mother­to­child transmission of HIV; PCR = polymerase chain reaction.
*N=956 unless otherwise stated.
†Excluding women who tested HIV­positive in late gestation after testing HIV­negative at booking.
‡Among women who started lifelong ART during pregnancy.
§Among women booking after 1 April 2010 who started ART before or during pregnancy.
¶Following antenatal counselling, the remainder of the women elected to formula feed.
||Total infants born less number of stillborn infants.
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All HIV­positive pregnant women (and 
their infants) who first attended the 
maternal facilities between 1 January 
2009 and 31 March 2012 and had 
available maternal dates of birth and 
dates of first antenatal visit (booking 
visit) were included in the analysis. 
Infants and their mothers were followed 
up (where possible) until the infants’ 
first HIV DNA polymerase chain 
reaction (PCR) test approximately 6 
weeks after delivery.
Before April 2010, HIV­positive 
pregnant women with CD4+ cell counts 
≤200 cells/µL or in World Health 
Organization (WHO) clinical stage 
IV were eligible to start lifelong triple 
antiretroviral therapy (ART). If ineligible 
for ART, pregnant women were to 
receive antenatal zidovudine (ZDV) 
from 28 weeks’ gestation until delivery 
and intrapartum single­dose nevirapine 
(sdNVP). Infants were to receive sdNVP 
immediately after delivery and a 7­day 
course of ZDV. From April 2010, ART 
eligibility criteria for pregnant women 
were expanded to include women with 
CD4+ cell counts ≤350 cells/µL or in 
WHO clinical stages III or IV. Women 
ineligible for ART were to receive 
antenatal ZDV from 14 weeks’ gestation 
and intrapartum sdNVP, as well as 
single­dose tenofovir/emtricitabine 
after delivery to cover the ‘NVP tail’. 
Infants received an extended NVP 
course, the duration being dependent 
on the duration of breastfeeding. 
Antenatal and intrapartum care was 
provided by nurses at the community 
health centres. Clinical mentoring for 
nurses was provided by quality nurse 
mentors (experienced roving nurses 
who support nurse clinical management 
skills) using a data­driven approach.
Definitions and outcomes
Adolescents were defined as aged 
≤19 years (at the first antenatal visit) 
and young women as aged ≤24 years, 
according to WHO definitions.[11] Older 
women were defined as >24 years of age.
The MTCT­related (primary) out­
comes analysed were: (i) proportions 
of HIV­positive pregnant women 
who were unaware of their positive 
HIV status at the booking visit;[12] 
(ii) duration of time from booking 
visit until initiation of lifelong ART 
antenatally, i.e. rate of antenatal ART 
take­up;[13] (iii) proportions of women 
who were receiving lifelong ART by 
delivery (initiated either before or T
ab
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during pregnancy);[14] (iv) proportions of 
women presenting for the first time when 
in labour (unbooked);[15] (v) proportions 
of liveborn infants with available first HIV 
DNA PCR test results at ~6 weeks of age 
(uptake of early infant diagnosis of HIV 
(EID));[16] and (vi) proportions of positive 
PCR tests (vertical HIV transmission at 6 
weeks).[14] Other maternal and child health 
(secondary) outcomes were: (i) proportions 
of women known to have died during the 
antenatal or early postnatal period (maternal 
mortality);[8] and (ii) proportions of stillborn 
infants.[8]
Data collection and statistical 
analysis
Enhanced routine clinical data (individual­
level patient data) were collected pro­
spectively by clinic­based data capturers in 
an electronic database after patient visits. 
Maternal HIV status and antenatal clinical 
details were captured from clinical files and 
clinic­based registers. Maternal mortality 
was recorded as reported to clinic staff. 
Infant follow­up data were sourced from 
child health services in the surrounding area 
by a PMTCT co­ordinator, as mothers would 
not necessarily return to the same maternal 
facility for child health visits. Clinical data 
were reviewed by quality nurse mentors as 
well as the district data co­ordinator before 
being sent to the Kheth’Impilo national 
office, where data from different facilities 
were merged.
Linear trends in maternal characteristics 
between women’s age categories were 
assessed using the Cochrane­Armitage and 
Cuzick’s non­parametric tests for categorical 
and continuous variables, respectively. 
Multivariable log­binomial regression was 
used to assess the effect of maternal age 
on binary outcomes. Kaplan­Meier curves, 
the log­rank trend test and multivariable 
Cox proportional hazards regression were 
used to estimate the association between 
maternal age and time to ART initiation 
during pregnancy among women who 
initiated ART antenatally. Women aged >24 
years were used as the comparison group 
in all regression models. Available a priori­
identified covariates considered as potential 
confounders that were eligible for inclusion 
in multivariable models were:[13,14] (i) year 
of first antenatal visit; (ii) newly diagnosed 
HIV­positive; (iii) gestational age at booking; 
(iv) maternal CD4+ cell count at booking; 
(v) antiretroviral regimen at delivery; (vi) 
duration of receiving antiretrovirals prior to 
delivery; (vii)  presenting for the first time 
during labour (unbooked); (viii)  infant 
feeding choice; and (ix) receipt of support 
from a community­based adherence worker. 
Plausible confounding covariates that 
produced a ≥10% shift in the crude effect 
measure of the main exposure of interest 
were included in multivariable models.[17] 
Data were analysed using Stata version 11.1. 
Ethical permission for the study was granted 
by the University of Cape Town Human 
Research Ethics Committee.
Results
Database records of 1 136 HIV­positive 
pregnant women and their infants were 
reviewed for inclusion in the study; 166 
who booked after 31 March 2012, 6 with 
missing maternal dates of birth and 8 with 
missing dates of first antenatal visit were 
excluded, leaving 956 mother­infant pairs 
to be included in analyses. Of the women, 
312 (32.6%) were ≤24 years old, and among 
these 65 (20.8%) were adolescents (age range 
13 ­ 19 years).
Maternal and infant characteristics are 
shown in Table 1, and associations between 
age categories and health outcomes in Table 
2. There was a relative increase of 24% 
(from 28.3% to 35.1%) in the proportion 
of HIV­positive women aged ≤24 years 
between 2009/2010 and 2011/2012 (crude 
risk ratio (RR) 1.24; 95% confidence interval 
(CI) 1.02 ­ 1.51). The median gestational 
age at booking was 22 weeks (interquartile 
range (IQR) 17 ­ 26), with no difference 
between age categories (p=0.76). Young 
women were progressively more unaware 
of their positive HIV status at booking, 
with 75.3% unawareness among adolescents 
compared with 44.7% among older women 
(crude RR 1.69; 95% CI 1.43 ­ 1.98). Young 
women had higher median CD4+ cell 
counts at booking (378 cells/µL (IQR 256  ­ 
500) v. 339 (217 ­ 477) in older women; 
p=0.005) and lower proportions with CD4+ 
cell counts <200  cells/µL (14.4% v. 21.5% 
in older women; p=0.010). None of the 
adolescents were receiving lifelong ART 
at booking (despite 10% having CD4+ cell 
counts <200  cells/µL), compared with 6.9% 
of women aged 20 ­ 24 years and 21.1% 
of older women who were receiving ART 
(p<0.0001).
The median time between the booking 
visit and commencement of antenatal ZDV 
for PMTCT was 5 days (IQR 0 ­ 48), with 
no difference between age groups (p=0.26). 
The median time between booking and ART 
initiation during pregnancy was substantially 
longer in adolescents (64 days) and women 
aged 20 ­ 24 years (48 days) compared with 
older women (34 days). Fig. 1 shows the 
Kaplan­Meier estimates of time to initiating 
lifelong ART between booking and delivery, 
indicating that younger women had lower 
probabilities of ART uptake at each time point 
after booking (p­trend = 0.0027). Following 
adjustment, adolescents and women aged 
20 ­ 24 years had rates of antenatal ART 
uptake that were more than 50% slower than 
that of older women (adjusted hazard ratio 
(aHR) 0.44; 95% CI 0.22 ­ 0.88 and aHR 
0.46; 95% CI 0.30 ­ 0.69, respectively). Other 
findings of interest were that ART uptake was 
more rapid in 2012 compared with previous 
years (p=0.0019), ART uptake was slower in 
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Fig. 1. Kaplan-Meier failure estimates of time to ART initiation (among women who initiated ART 
during pregnancy) according to age categories. (ART = antiretroviral therapy.)
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women with booking gestational ages of ≤16 
weeks (p=0.0001), and ART uptake was more 
rapid among women who received support 
from a community­based adherence support 
worker (p=0.0053) (Fig. 2).
The proportion of women who were first 
identified as HIV­positive in late gestation 
(32 ­ 34 weeks) after testing HIV­negative at 
the booking visit was higher among young 
women (3.0% v. 1.5% in older women: crude 
RR 2.06; 95% CI 0.90 ­ 4.70).
By the time of delivery, the proportions 
of women who were receiving lifelong 
ART were 27.7%, 32.0% and 45.2% among 
adolescents, women aged 20 ­ 24 years 
and older women, respectively (p=0.001). 
Despite adjusting for CD4+ cell counts and 
gestational age at booking, young women 
had increased probabilities of not receiving 
lifelong ART by delivery (adjusted risk 
ratio (aRR) 1.37; 95% CI 1.29 ­ 1.45 for 
adolescents and aRR 1.13; 95% CI 1.05 ­ 1.21 
for women aged 20 ­ 24 years).
The median duration of receiving lifelong 
ART prior to delivery was significantly shorter 
in adolescents (15.1 weeks) and women aged 
20 ­ 24 years (14.4 weeks) compared with 
older women (21.1 weeks) (p<0.0001). The 
proportions of women who received lifelong 
ART for <14 weeks prior to delivery were 
50.0% in adolescents, 48.3% in women aged 
20 ­ 24 years and 29.5% in older women 
(crude RR 1.64; 95% CI 1.18 ­ 2.28 for young 
women v. older women). In contrast, there 
was no difference in the median duration 
of receiving ZDV for prophylaxis of MTCT 
before delivery according to maternal age 
(16.9 weeks (IQR 10 ­ 21.4); p=0.34).
Adolescents had a substantially increased 
risk of first presentation during labour (4.6% 
v. 1.7% in older women: aRR 3.78; 95% CI 
1.06 ­ 13.4). In addition, women with known 
HIV­positive status (included in the adjusted 
model as a confounder) also had a higher 
risk of presenting for the first time during 
labour (aRR 2.80; 95% CI 1.06 ­ 7.40).
Maternal mortality was increased in 
adolescents (2.5% v. 0% in older women: 
aRR  35.1; 95% CI 2.89 ­ 426; p=0.005) 
(adjusted for baseline CD4+ cell count, ART 
regimen, year of booking and unbooked 
status). The risk of stillbirth was also 
substantially greater in adolescents (9.4% 
v. 5.0% in older women: aRR 3.33; 95% 
CI 1.53 ­ 7.25; p=0.002) (adjusted for maternal 
CD4+ cell count, year of booking, gestational 
age at booking, and receipt of community­
based adherence worker). Women who were 
supported by community­based adherence 
support workers had a substantially lower 
risk of stillbirth (0.5% v. 5.9% among women 
without a community support worker: 
aRR=0.09; 95% CI 0.12 ­ 0.65; p=0.017).
HIV transmission
Four hundred and sixty­eight results of 
first infant HIV PCR tests were available, 
with overall uptake of EID of 51.4% 
(468/910) and overall HIV transmission 
of 3.4% (16/468). Young women had a 
slightly reduced uptake of EID (aRR 0.94; 
95% CI 0.94 ­ 0.94). Crude vertical HIV 
transmission rates were 8.3%, 6.5% and 
2.1% among adolescent mothers, women 
aged 20  ­ 24 years and older women, 
respectively (p­trend = 0.011). The majority 
Fig. 2. Kaplan-Meier failure estimates of time to antenatal ART initiation according to: A) year of 
booking, B) gestational age at booking categories, and C) receipt of community adherence support 
worker. (ART = antiretroviral therapy; GA = gestational age at fi rst antenatal clinic visit.)
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of vertical transmissions (56.3%) occurred among young women 
(p=0.011), even though young women constituted only a third of 
the total cohort. In multivariable analyses, younger women had 
progressively increased risks of vertical HIV transmission (aRR 4.48; 
95% CI 1.32 ­ 15.2; p=0.016 among adolescents and aRR 2.84; 95% 
CI 1.02 ­ 7.90; p=0.045 among women aged 20 ­ 24 years) (adjusted 
for ART regimen and unbooked status). Women who presented for 
the first time during labour had a greatly increased risk of vertical 
transmission (aRR 10.5; 95% CI 3.62 ­ 30.2; p<0.0001).
Discussion
We found that young women in the NMBM district in the Eastern 
Cape were less aware of their HIV status when booking than older 
women, and had slower antenatal ART uptake, reduced uptake of 
EID and increased MTCT of HIV (despite having less advanced 
immunosuppression). In addition, adolescents had increased 
risks of maternal mortality, first presentation in labour, and 
stillbirth. These findings have important public health relevance 
in SA, particularly as young women formed a third of all pregnant 
women, and increasing proportions of young women presented 
over time.
Younger women are probably less aware of their HIV status 
because they are more likely to be having their first pregnancy; as 
antenatal attendance is an important entry point for HIV testing, 
women with previous pregnancies are more likely to know their HIV 
status. High rates of undiagnosed HIV infection among adolescents 
have also been found in Zimbabwe.[18]
The increased HIV transmission in younger women is probably 
related to a combination of factors. Few young women became 
pregnant while already receiving ART (probably primarily because 
they were less aware of their HIV status, and secondarily, for 
those accessing services, because they were earlier in the course of 
HIV disease and so less likely to be eligible for ART). Initiation of 
ART during pregnancy was also slower in young women. Eligible 
women were referred to start ART at dedicated ART clinics at 
these facilities, and delays among younger women may have been 
related to challenges that particularly affect that age group, including 
concerns over confidentiality, social stigma[19] and interpersonal 
relational barriers with healthcare workers.[20] By the time of delivery, 
smaller proportions of young women were receiving ART, and for 
shorter durations of time. In contrast, older women were more likely 
to start ART before becoming pregnant, and started ART more 
rapidly during pregnancy. Each additional week of antenatal ART 
is known to significantly reduce vertical transmission.[14] Increased 
seroconversion during late pregnancy among young women may also 
play a role, as 34% of MTCT in South Africa has been estimated to 
be due to women seroconverting after their first antenatal visit.[21] An 
additional contributory factor may have been decreased adherence to 
antiretrovirals, as has been found among adolescents receiving lifelong 
ART.[22] A recently published cross­sectional survey from KwaZulu­
Natal also found increased MTCT among adolescent mothers,[23] but 
did not analyse young women as a separate group. Further research 
should be conducted to establish the relative contribution of factors 
resulting in vertical transmission among young women.
Since April 2013, HIV­positive pregnant SA women have been 
eligible to start triple ART at the time of diagnosis irrespective of 
CD4+ cell count, and a pilot study had shown this approach to be safe 
and feasible and to be associated with low MTCT.[24] The results of our 
study suggest that programmes to reduce adolescent pregnancies, 
expanded adolescent HIV counselling and testing programmes 
(including implementation of the Integrated School Health 
Programme), early detection of young women who seroconvert 
during pregnancy, and transforming reproductive health services to 
be more youth and adolescent friendly[9,10] may also lead to reduced 
MTCT. Early identification of young pregnant women who are HIV­
positive, swift initiation of triple ART and providing youth­centred 
ART adherence support to these women need to be important 
priorities for prevention of MTCT programmes. Measures to improve 
EID among young mothers in particular, to identify infants eligible 
to start ART, also need to be prioritised. There is a critical need for 
sexual and reproductive health rights to be rolled out at clinics as well 
as at schools, with increased access to HIV counselling and testing, 
barrier methods and family planning.
Study strengths and limitations
A strength of the study is that it is from an under­resourced area from 
which there are few published data on MTCT programme outcomes. 
The limitations of the study include the use of routine data, and 
missing early infant HIV DNA PCR results that may have led to bias 
and reduced the precision of transmission effect measures. However, 
all the outcomes pointed in the same direction. Estimates of EID 
uptake in SA have previously been as low as 35% in 2010.[16] This 
highlights the difficulty of tracking mother­infant pairs in routine 
settings, and is due to a combination of reasons: mothers taking 
infants for testing at a number of different child health facilities so 
that infants are not able to be traced; mothers not bringing infants 
for testing; late testing of infants; and results not being able to be 
tracked from the laboratory. An additional study limitation was that 
accurate ART eligibility among pregnant women was not able to be 
ascertained, as WHO clinical stages were not captured electronically.
Conclusion
Adolescent and young pregnant women were found to have a high risk 
of MTCT and to have poorer maternal and infant health outcomes 
than older women. Programmes targeting a reduction in adolescent 
pregnancies, expanded adolescent HIV testing, transforming 
reproductive services to be more adolescent and youth friendly, and 
improving early infant HIV diagnosis, particularly among babies 
born to young mothers, may be important interventions to improve 
maternal and children’s health outcomes in SA.
Acknowledgements. The authors thank the mothers and infants included 
in the study, staff at the participating clinics, the Kheth’Impilo monitoring 
and evaluation team, the Eastern Cape Department of Health, the 
President’s Emergency Plan for AIDS Relief and USAID.
References
1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: WHO, 2013. 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/
UNAIDS_Global_Report_2013_en.pdf (accessed 26 February 2014).
2. Willan S. A review of teenage pregnancy in South Africa – experiences of schooling, and knowledge and 
access to sexual & reproductive health services. 2013. http://www.hst.org.za/sites/default/files/Teenage%20
Pregnancy%20in%20South%20Africa%20Final%2010%20May%202013.pdf (accessed 26 February 2014).
3. Khan S, Mishra V. Youth Reproductive and Sexual Health. DHS Comparative Reports No. 19. 
Calverton, Md, USA, 2008. http://pdf.usaid.gov/pdf_docs/PNADM644.pdf (accessed 2 March 2014).
4. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people’s sexual health in South Africa: HIV prevalence 
and sexual behaviors from a nationally representative household survey. AIDS 2005;19(14):1525­1534.
5. Actuarial Society of South Africa. ASSA2008 AIDS and Demographic Model. 2011. http://aids.
actuarialsociety.org.za/ASSA2008­Model­3480.htm (accessed 18 March 2011).
6. Simbayi LC, Shisana O, Rehle T, et al. South African National HIV Prevalence, Incidence and 
Behaviour Survey. Cape Town, 2012. http://www.hsrc.ac.za/en/research­outputs/view/6871 (accessed 
15 June 2014).
7. Schoon M, Motlolometsi M. Poor maternal outcomes: A factor of poor professional systems design. S 
Afr Med J 2012;102(10):784­786. [http://dx.doi.org/10.7196/SAMJ.6130]
8. Rollins N, Coovadia H, Bland R, et al. Pregnancy outcomes in HIV­infected and uninfected women 
in rural and urban South Africa. J Acquir Immune Defic Syndr 2007;44(3):321­328. [http://dx.doi.
org/10.1097/QAI.0b013e31802ea4b0]
9. United Nations. Global Strategy for Women’s and Children’s Health. New York, 2010. http://www.who.
int/pmnch/topics/maternal/20100914_gswch_en.pdf (accessed 27 February 2014).
10. Fatti G, Meintjes G, Shea J, et al. Improved survival and antiretroviral treatment outcomes in 
adults receiving community­based adherence support: 5­year results from a multicentre cohort 
study in South Africa. J Acquir Immune Def Syndr 2012;61(4):e50­e58. [http://dx.doi.org/10.1097/
QAI.0b013e31826a6aee]
879       December 2014, Vol. 104, No. 12
RESEARCH
11. World Health Organization. The Health of Youth. Document A42/Technical Discussions/2. Geneva: 
WHO, 1989.
12. Grimwood A, Fatti G, Mothibi E, et al. Progress of preventing mother­to­child transmission of HIV 
at primary healthcare facilities and district hospitals in three South African provinces. S Afr Med J 
2012;102(2):81­83.
13. Stinson K, Jennings K, Myer L. Integration of antiretroviral therapy services into antenatal care
increases treatment initiation during pregnancy: A cohort study. PLoS ONE 2013;8(5):e63328. [http://
dx.doi.org/10.1371/journal.pone.0063328]
14. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and 
regimen on risk for mother­to­child transmission of HIV in Johannesburg, South Africa. J Acquir 
Immune Defic Syndr 2010;54(1):35­41. [http://dx.doi.org/10.1097/QAI.0b013e3181cf9979]
15. Okeudo C, Ezem B, Ojiyi E. Unbooked status: A predictor of adverse perinatal outcome in HIV
positive women at a tertiary hospital in the South Eastern Nigeria. Afrimedic J 2011;2(2):17­20.
16. Goga AE, Dinh TH, Jackson DJ, et al. Evaluation of the Effectiveness of the National Prevention
of Mother­to­Child Transmission (PMTCT) Programme on Infant HIV Measured at Six Weeks
Postpartum in South Africa, 2010. South African Medical Research Council, National Department 
of Health of South Africa and PEPFAR/US Centers for Disease Control and Prevention, 2012. http://
www.mrc.ac.za/healthsystems/SAPMTCTE2010.pdf (accessed 17 August 2012).
17. Maldonado G, Greenland S. Simulation study of confounder­selection strategies. Am J Epidemiol
1993;138(11):923­936.
18. Ferrand RA, Munaiwa L, Matsekete J, et al. Undiagnosed HIV infection among adolescents
seeking primary health care in Zimbabwe. Clin Infect Dis 2010;51(7):844­851. [http://dx.doi.
org/10.1086/656361]
19. Forrest J, Kaida A, Dietrich J, et al. Perceptions of HIV and fertility among adolescents in Soweto, 
South Africa: Stigma and social barriers continue to hinder progress. AIDS Behav 2009;13(1):55­61. 
[http://dx.doi.org/10.1007/s10461­009­9552­z]
20. Alli F, Maharaj P, Vawda M. Interpersonal relations between health care workers and young clients: 
Barriers to accessing sexual and reproductive health care. J Commun Health 2013;38(1):150­155.
[http://dx.doi.org/10.1007/s10900­012­9595­3]
21. Johnson LF, Stinson K, Newell M­L, et al. The contribution of maternal HIV seroconversion during late 
pregnancy and breastfeeding to mother­to­child transmission of HIV. J Acquir Immune Defic Syndr 
2012;59(4):417­425. [http://dx.doi.org/10.1097/QAI.0b013e3182432f27]
22. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic 
outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr
2009;51(1):65­71. [http://dx.doi.org/10.1097/QAI.0b013e318199072e]
23. Horwood C, Butler LM, Haskins L, et al. HIV­infected adolescent mothers and their infants: Low 
coverage of HIV services and high risk of HIV transmission in KwaZulu­Natal, South Africa. PLoS 
ONE 2013;8(9):e74568. [http://dx.doi.org/10.1371/journal.pone.0074568]
24. Black S, Zulliger R, Myer L, et al. Safety, feasibility and efficacy of a rapid ART initiation in pregnancy 
pilot programme in Cape Town, South Africa. S Afr Med J 2013;103(8):557­562. [http://dx.doi.
org/10.7196/SAMJ.6565]
Accepted 14 August 2014.
880       December 2014, Vol. 104, No. 12
